Prevalence and Pathophysiology of Systemic Arterial Pressure Abnormalities in Childhood Sickle Cell Disease (DrépaPA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04911049 |
Recruitment Status :
Recruiting
First Posted : June 2, 2021
Last Update Posted : October 18, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Sickle Cell Disease | Diagnostic Test: Blood Pressure measurement |
Study Type : | Observational |
Estimated Enrollment : | 200 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | Prevalence and Pathophysiology of Systemic Arterial Pressure Abnormalities in Childhood Sickle Cell Disease |
Actual Study Start Date : | June 1, 2021 |
Estimated Primary Completion Date : | June 1, 2023 |
Estimated Study Completion Date : | June 1, 2023 |

- Diagnostic Test: Blood Pressure measurement
Blood Pressure measurement
- Ambulatory Blood Pressure Monitoring (ABPM) [ Time Frame: 2 years ]mean, systolic and diastolic arterial pressure

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- child (age <18 years);
- sub-Saharan or Caribbean origin;
- major sickle cell disease (SS, SC and Sbeta-thalassemia);
- height ≥ 120 cm; absence of treated hypertension or antihypertensive treatment;
- parents informed and not opposed to participation in research
Exclusion Criteria:
-

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04911049
Contact: Christophe DELCLAUX, MD, PhD | +331 40 03 41 90 | christophe.delclaux@aphp.fr | |
Contact: Bérengère KOEHL, MD | berengere.koehl@aphp.fr |
France | |
Robert Debre Hospital | Recruiting |
Paris, France, 75019 | |
Contact: Christophe Delclaux, MD PhD +33 1 40 03 41 90 christophe.declaux@aphp.fr |
Principal Investigator: | Bérengère KOEHL, MD | Assistance Publique - Hôpitaux de Paris |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT04911049 |
Other Study ID Numbers: |
APHP201318 |
First Posted: | June 2, 2021 Key Record Dates |
Last Update Posted: | October 18, 2021 |
Last Verified: | May 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
sickle cell disease systemic hypertension |
Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia |
Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn |